醫藥股捱沽 麗珠(01513.HK)隨A股瀉12% 翰森(03692.HK)挫10%創上市低
恆指今早(7日)低開後反覆回軟,高低見19,581/19,352,現報19,516,回吐22點或0.1%,總成交額324億元。
醫藥股今早普遍捱沽,尤其是麗珠醫藥(01513.HK)急挫12%報23.8元,股價失守250天、20天、10天及50天線(介乎25.5至26.9元);麗珠A(000513.SZ)早市跌停。
藍籌翰森製藥(03692.HK)創上市新低,最低見10.2元,現報10.24元,下挫10%。翰森上周五(4日)收市後公布,收到EQRx終止其與附屬有關阿美替尼許可協議的通知。
藍籌股藥明生物(02269.HK)、石藥(01093.HK)、中生製藥(01177.HK)、以及非藍籌藥明康德(02359.HK)、三生製藥(01530.HK)、維亞生物(01873.HK)、3D MEDICINES(01244.HK)、康希諾生物(06185.HK)、先聲藥業(02096.HK)、君實生物(01877.HK)、科倫博泰生物-b(06990.HK)、金斯瑞(01548.HK)、百濟神州(06160.HK)、康方生物(09926.HK)、泰格醫藥(03347.HK)、榮昌生物(09995.HK)、信達生物(01801.HK)及康諾亞-B(02162.HK)挫逾3%至逾9%不等;後三者跌幅最大,分別報37.5元、29.8元及48.2元(跌破250天線50.88元),各挫逾9%。
另外,海吉亞醫療(06078.HK)亦挫半成,報45.2元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.